Chronic Disease
Featured Topics
Lead story
Other featured articles
-
Early Transplantation Maximizes Survival in Severe Acute-On-Chronic Liver Failure: Results of a Markov Decision Process Model
The researchers create a Markov decision process model to maximize overall survival among patients listed for liver transplantation with grade three acute-on-chronic liver failure (ACLF-3) within the first 7 days of listing
Posted in -
After Their Initial Diagnosis, Many Adult COVID-19 Patients Continue Seeking Medical Care for up to Six Months or More
Analyzing claims data, does COVID-19 related healthcare utilization persist in for 180 days or more, also known as long COVID, after their initial diagnosis?
Posted in -
Multi-Cancer Blood Tests Can Reduce Late-Stage Cancer Diagnosis in Black and Latino Patients
A new white paper published by the USC Schaeffer Center focuses on the potential benefit of multi-cancer early detection (MCED) blood-based tests to reduce disparities in late-stage cancer diagnosis among minority populations.
Posted in -
Latinos Are More Likely to Die From COVID-19, Underlining Racial and Ethnic Disparities in Outcomes
Latinos were tested more for COVID-19 and had higher rates of infection, hospitalization and death.
Posted in
About this section
Chronic diseases are among the most preventable and costliest conditions, consuming the overwhelming majority of Medicare resources. The Schaeffer Center assembles leading minds from across disciplines to address this challenge, striving to simplify labyrinthine systems of care and promote healthier outcomes.
Our Experts On Chronic Disease
Our Work In Chronic Disease
-
Reducing Racial Disparities in Early Cancer Diagnosis With Blood-Based Tests
A new white paper published by the USC Schaeffer Center focuses on multi-cancer, early detection, (MCED) blood-based tests as one solution to reduce disparities in late-stage cancer diagnosis among minority populations.
Categorized in -
Measuring Real-World Effectiveness and Value
Precision therapies are often approved based on small trials, in specialized settings, and using biomarkers as endpoints. Thus, despite their potential high cost, the evidence of value is lacking which makes real-world evidence crucial.
-
Leveraging Precision Medicine to Meet Patient Needs
Precision medicine promises to reduce adverse side effects and time-consuming trial and error processes, but many patients do not know what it is and providers struggle to leverage it effectively.
-
Cost- Effectiveness of Total State Coverage for Hepatitis C Medications
A Medicaid-Medicare partnership could cover lifesaving hepatitis C medications — and still save $1 to $1.1 billion over 25 years.
Categorized in -
Comparison of Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Bioprosthetic Heart Valves
Use of direct oral anticoagulants gradually increased since 2011, with a significant upward in trend after a stay-at-home order related to COVID-19.
Categorized in -
Congress Should End Dialysis Companies’ Third-Party Games with Insurance Coverage
A new op-ed in STAT highlights practices by dialysis facilities where they try to push patients into individual market plans by financing patients’ premiums for those plans